scholarly journals Dynamics of Preferential Substrate Recognition in HIV-1 Protease: Redefining the Substrate Envelope

2011 ◽  
Vol 410 (4) ◽  
pp. 726-744 ◽  
Author(s):  
Ayşegül Özen ◽  
Türkan Haliloğlu ◽  
Celia A. Schiffer
2014 ◽  
Vol 70 (a1) ◽  
pp. C116-C116
Author(s):  
Celia Schiffer

Drug resistance negatively impacts the lives of millions of patients and costs our society billions of dollars by limiting the longevity of many of our most potent drugs. Drug resistance can be caused by a change in the balance of molecular recognition events that selectively weakens inhibitor binding but maintains the biological function of the target. To reduce the likelihood of drug resistance, a detailed understanding of the target's function is necessary. Both structure at atomic resolution and evolutionarily constraints on its variation is required. "Resilient" targets are less susceptible to drug resistance due to their key location in a particular pathway. This rationale was derived through crystallographic studies elucidating substrate recognition and drug resistance in HIV-1 protease and Hepatitis C (HCV) NS3/4A protease. Both are key therapeutic targets and are potentially "resilient" targets where resistant mutations occur outside of the substrate binding site. To reduce the probability of drug resistance inhibitors should be designed to fit within what we define as the "substrate envelope". These principals are likely more generally applicable to other quickly evolving diseases where drug resistance is quickly evolving. http://www.umassmed.edu/schifferlab/index.aspx


2013 ◽  
Vol 20 (9) ◽  
pp. 1116-1124 ◽  
Author(s):  
Madhavi N.L. Nalam ◽  
Akbar Ali ◽  
G.S. Kiran Kumar Reddy ◽  
Hong Cao ◽  
Saima G. Anjum ◽  
...  

2008 ◽  
Vol 22 (S1) ◽  
Author(s):  
Zhigang Liu ◽  
Ravikiran Yedidi ◽  
Joseph Brunzelle ◽  
Iulia Kovari ◽  
Ladislau Kovari

2019 ◽  
Vol 62 (17) ◽  
pp. 8062-8079 ◽  
Author(s):  
Linah N. Rusere ◽  
Gordon J. Lockbaum ◽  
Sook-Kyung Lee ◽  
Mina Henes ◽  
Klajdi Kosovrasti ◽  
...  

2010 ◽  
Vol 114 (7) ◽  
pp. 2525-2532 ◽  
Author(s):  
M. A. S. Perez ◽  
P. A. Fernandes ◽  
M. J. Ramos

2006 ◽  
Vol 80 (7) ◽  
pp. 3607-3616 ◽  
Author(s):  
Moses Prabu-Jeyabalan ◽  
Ellen A. Nalivaika ◽  
Keith Romano ◽  
Celia A. Schiffer

ABSTRACT Human immunodeficiency virus type 1 (HIV-1) protease processes and cleaves the Gag and Gag-Pol polyproteins, allowing viral maturation, and therefore is an important target for antiviral therapy. Ligand binding occurs when the flaps open, allowing access to the active site. This flexibility in flap geometry makes trapping and crystallizing structural intermediates in substrate binding challenging. In this study, we report two crystal structures of two HIV-1 protease variants bound with their corresponding nucleocapsid-p1 variant. One of the flaps in each of these structures exhibits an unusual “intermediate” conformation. Analysis of the flap-intermediate and flap-closed crystal structures reveals that the intermonomer flap movements may be asynchronous and that the flap which wraps over the P3 to P1 (P3-P1) residues of the substrate might close first. This is consistent with our hypothesis that the P3-P1 region is crucial for substrate recognition. The intermediate conformation is conserved in both the wild-type and drug-resistant variants. The structural differences between the variants are evident only when the flaps are closed. Thus, a plausible structural model for the adaptability of HIV-1 protease to recognize substrates in the presence of drug-resistant mutations has been proposed.


2008 ◽  
Vol 130 (19) ◽  
pp. 6099-6113 ◽  
Author(s):  
Michael D. Altman ◽  
Akbar Ali ◽  
G. S. Kiran Kumar Reddy ◽  
Madhavi N. L. Nalam ◽  
Saima Ghafoor Anjum ◽  
...  

2007 ◽  
Vol 68 (2) ◽  
pp. 561-567 ◽  
Author(s):  
Sripriya Chellappan ◽  
Visvaldas Kairys ◽  
Miguel X. Fernandes ◽  
Celia Schiffer ◽  
Michael K. Gilson
Keyword(s):  
Hiv 1 ◽  

Sign in / Sign up

Export Citation Format

Share Document